Skip to main content

Table 2 Clinical Outcomes of RFA vs. no RFA in NVAF patients taking DOACs

From: Safety and efficacy of direct oral anticoagulation in patients with and without radiofrequency ablation of non-valvular atrial fibrillation: a multicenter retrospective cohort study

 

No RFA (n=3476)

RFA (n=2661)

OR(95%CI)

P value

Adjusted OR(95%CI)b

P value

Total bleeding, n(%)

405(11.7)

265(9.9)

0.839(0.712-0.988)

<0.001

0.901(0.746-1.087)

0.275

Major Bleeding, n(%)

98(2.8)

15(0.6)

0.195(0.113-0.337)

0.035

0.278(0.150-0.515)

<0.001

Thrombosis, n(%)

58(1.7)

25(0.9)

0.559(0.349-0.896)

0.014

0.535(0.316-0.908)

0.020

All-cause death, n(%)

178(5.1)

73(2.7)

0.523(0.396-0.690)

<0.001

0.842(0.611-1.160)

0.293

Composite outcomea, n(%)

624(18.0)

355(15.7)

0.704(0.611-0.810)

<0.001

0.835(0.710-0.982)

0.029

  1. NVAF Non-valvular atrial fibrillation, RFA Radiofrequency ablation, OR Odds ratio, 95%CI 95% Confidence interval
  2. aComposite outcome included all-cause death, thrombosis and total bleeding
  3. bAdjust for radiofrequency ablation, sex (male), age, body mass index, smoking, alcohol, hypertension, diabetes mellitus, heart failure, coronary artery disease, renal insufficiency, hypohepatia, vascular disease, total bilirubin, ghrelin, glutamic aminotransferase, creatinine, platelet count, hemoglobin, antiplatelet agents, proton pump inhibitors, H2 receptor antagonists, statins, amiodarone, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, digoxin, calcium blockers, diltiazem